Abstract 197P
Background
Tumor mutation burden, intratumor heterogeneity and the cancer related immune infiltrate are associated with response to target and immune therapies in several cancer types. The aim of this study is to establish a computational pathology (CPath) pipeline for investigating useful histopathological features in hematoxylin and eosin (H&E) whole slide images (WSIs). The pipeline allows for the segmentation and classification of nuclei. As an application, a machine learning approach is used to quantify intratumor heterogeneity (ITH) and tumor-infiltrating lymphocyte (TIL) scores.
Methods
We randomly selected 178 invasive ductal carcinomas WSIs from the TCGA database to process. Image annotation and nuclei detection were performed on QuPath by a pathologist using StarDist and used to train a SVM-based nuclei type classifier. The classifier was trained to distinguish between tumor, lymphocyte, and stroma. A total of 113.211 nuclei images were extracted using OpenSlide and used to train an autoencoder for dimensionality reduction. The variability of the WSIs was computed by applying a statistical measure of dispersion to the feature vectors. The TIL score was computed as the average minimum distance between a tumor cell and its nearest lymphocyte neighbor. We used the mutation burden, the ITH, PAM50 classification, nuclear and histological grades data from [https://doi.org/10.1038/nm.3984] to validate our ITH score. The percentage of infiltrating lymphocytes inferred by the quanTIseq pipeline based on RNAseq data was used to validate the SVM model.
Results
The nuclei classifier achieved 88% accuracy on the test set and the 96%/92% sensitivity to tumor/lymphocyte on a validation dataset. The mean squared error of the autoencoder was 0.0004 in the test set. The ITH score was associated with the clonal number of a tumor (x2 = 8.8, p= 0.03). Finally, we observed a positive correlation between the TIL/tumor ratio inferred by the CPath pipeline and the total number of T lymphocytes inferred by quanTIseq (Spearman= 0. 34, p < 0.0001).
Conclusions
We explored a CPath pipeline for detecting and classifying nuclei. The pipeline was used to compute ITH and TIL scores which correlated with validation data. Thus, validating our pipeline.
Legal entity responsible for the study
D.G. Tiezzi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display
101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study
Presenter: Ramon Yarza
Session: Poster Display
102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
Presenter: Oladapo Yeku
Session: Poster Display
103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Presenter: Saby George
Session: Poster Display
105P - Preliminary efficacy and safety results from ‘ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.
Presenter: Yijun Shen
Session: Poster Display
106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study
Presenter: Amanda Psyrri
Session: Poster Display
108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL
Presenter: Bart Neyns
Session: Poster Display
109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy
Presenter: Inge Noringriis
Session: Poster Display
110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary
Presenter: Harpreet Wasan
Session: Poster Display